OrientBio to Integrate and Operate Gapyeong Center 1 and Center 2

OrientBio will integrate and operate its Gapyeong Center 1 and Center 2 in Gyeonggi-do.

According to OrientBio on July 29, this decision is a measure to streamline previously separated production facilities into a single system, reducing redundant work and maximizing the utilization of facilities and human resources. Through this integration, the company aims to boost production efficiency and cost competitiveness, thereby initiating improvements in profitability.

The Gapyeong Center 1 and Center 2 comprise the nation’s largest laboratory animal production complex, located on approximately 8,000 pyeong of land and equipped with 12 advanced animal housing buildings. Center 1 houses an internationally certified, high-quality, germ-free laboratory animal production facility and research institute. Center 2 operates laboratory animal production facilities that meet Specific Pathogen-Free (SPF) and Virus Antibody-Free (VAF) standards.

Both centers produce a diverse range of research rodents, such as mice and guinea pigs, based on the International Genetic Standard (IGS) line originated from Charles River in the United States. These laboratory animals are supplied to domestic pharmaceutical and biotech companies, universities, and government-funded research institutes, serving as key biological resources that underpin Korea’s bio research and development efforts.

With the integration of operations, OrientBio plans to optimize the allocation of production schedules and breeding spaces, as well as unify the management of production information and quality control systems. The company intends to respond more swiftly and flexibly to changing demands from research institutes and to enhance product uniformity and reliability by standardizing quality control criteria.

The company is also pursuing future growth businesses, including the expansion of its nonhuman primate (NHP) non-clinical contract research organization (CRO) operations in Cambodia and the establishment of an artificial intelligence (AI)-driven non-clinical platform. Through the integrated operation of the Gapyeong Centers, OrientBio expects to enhance the operational competitiveness of its existing laboratory animal business, thereby strengthening growth potential and profitability.

An OrientBio representative said, “The decision to integrate operations is a strategic move to raise productivity and quality management levels, while simultaneously enhancing cost competitiveness. Based on Korea’s top-tier laboratory animal production infrastructure, we will provide stable and highly reliable research biological resources, and continue to drive operational efficiency to improve our corporate competitiveness and profitability.”

This content was produced with the assistance of AI translation services.